Acute and Maintenance Treatment of Bipolar Disorder: Expert Perspectives

Sponsored by the NYU Post-Graduate Medical School

Release Date: April 20, 2009
Expiration Date: April 19, 2010

For further information about this internet CME activity, please contact the NYU Post-Graduate Medical School at 212-263-5295

For further information about NYU's Privacy and Confidentiality Policy, please visit:
http://www.med.nyu.edu/about/policies/privacy.html

Hardware and Software Requirements:

-Standard Web Browser
-Adobe Flash Player (To download Adobe Flash Player, please click here)
 -Adobe Reader (To download Adobe Reader, please click here)
 -A working sound card and speakers (or headphones)
-Broadband connection for optimal viewing

TARGET AUDIENCE

The target audience for this activity is psychiatrists and allied healthcare professionals with an interest in bipolar disorder.

COURSE DESCRIPTION

Bipolar disorder is a devastating psychiatric disease associated with significant morbidity and mortality. Current epidemiology supports the estimate of 5% for the prevalence of this disorder in the general population. There is no consensus, at this point, with respect to diagnosis and treatment of bipolar disorder. Given its prevalence and the severe impact of the disorder on the patient, his or her family, and on society as a whole, improved diagnosis and more effective selection and use of medications are needed.

STATEMENT OF NEED

This program represents a unique opportunity for clinicians to learn from and interact with a faculty of nationally recognized experts on the diagnosis and treatment of bipolar disorder. In addition to focusing on the issues surrounding the diagnostic boundaries of bipolar and unipolar disorders, the presentations will address emerging findings about the neurobiology of bipolar disorder, the long-neglected cognitive dimension of the disorder, and how these relate to treatment decisions. In terms of treatment, attendees will benefit from a review of the potential benefits and risks associated with both longstanding and newer therapeutic options and how they compare to older mood stabilizers.

EDUCATIONAL OBJECTIVES

  • Describe how treatment may impact prefrontal and limbic circuitry and may decrease the risk of future structural alterations
  • Explain the barriers to accurate diagnosis of patients with bipolar disorder and unipolar depression and list ways to overcome them
  • Review existing bipolar disorder diagnostic guidelines and describe how emerging evidence might modify these guidelines so that they more accurately reflect clinical reality
  • Discuss the importance of appropriate diagnosis in bipolar disorder patients, especially considering the alarming rate of misdiagnosis
  • Evaluate the risks/benefits of therapeutic options for bipolar disorder and consider the possibility of neuroprotection in deciding to initiate treatment
  • Detail the clinical implications of early pharmacologic intervention on cognition and course of illness
  • Recognize the correlation between early, effective treatment of mood disorders, rates of remission, and subsequent unlikelihood of relapse and recurrence
  • Review pharmacologic therapeutic options for treating bipolar disorder in terms of efficacy and safety profiles and incorporate this information to select patient-specific therapy

ACCREDITATION STATEMENT

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The NYU Post-Graduate Medical School designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credits.™ Physicians should only claim credits commensurate with the extent of their participation in the activity.

FACULTY LIST

P. Murali Doraiswamy, MD
Chief, Division of Biological Psychiatry
Department of Psychiatry
Duke University Medical Center

S. Nassir Ghaemi, MD MPH
Professor of Psychiatry
Tufts University School of Medicine
Director, Mood Disorders Program
Tufts Medical Center

Joseph L. Goldberg, MD
Clinical Associate Professor of Psychiatry
Mount Sinai School of Medicine

J. Craig Nelson, MD
Professor in Residence
Department of Psychiatry
University of California, San Francisco

Jerrold F. Rosenbaum, MD
Psychiatrist-in-Chief
Massachusetts General Hospital
Stanley Cobb Professor of Psychiatry,
Harvard Medical School

DISCLOSURE STATEMENT

It is the policy of the NYU Post Graduate Medical School to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored activities. Because CME activities are conducted in the public interest, it is important to assure the public that education received by physicians and other health care professionals through whom patient care decisions are made is conducted with the highest integrity, scientific objectivity and in the absence of bias. A conflict of interest exists when individuals have both a relevant financial relationship with a commercial interest and the opportunity to affect the content of CME about the product or services of that commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) holds providers of CME responsible for collecting information from its instructors, planners and managers of CME content and resolving those conflicts prior to the commencement of the CME activity. The intent of the conflict of interest resolution process is to assure that provider, faculty and planner relevant financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

The following have indicated whether they have received financial support for consultation, research or evaluation, have a financial interest relative to their presentation or will include the discussion of the
unlabeled or unapproved use of a drug, device or procedure:

P. Murali Doraiswamy, MD – Presenter – serves as a consultant to Eli Lilly & Co.,
Forest Pharmaceuticals, and Sonexa Therapeutics. He serves on the speakers’ bureau of
Otsuka America Pharmaceuticals, Inc., Forest Pharmaceuticals and Eli Lily & Co. He is the recipient of research funding from Elan Pharmaceuticals and has an ownership interest in Sonexa Therapeutics.
Dr. Doraiswamy’s presentation may include discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., the effects of psychotropics on brain imaging markers.

S. Nassir Ghaemi, MD – Presenter - serves on the speakers’ bureau of Pfizer, Inc. and AstraZeneca Pharmaceuticals LP. He is the recipient of research funding from Pfizer, Inc. Dr. Ghaemi’s presentation will include discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e, all antidepressants used to treat bipolar disorder.

Joseph F. Goldberg, MD – Presenter – is the recipient of royalty payments from American Psychiatric Press, Inc. He serves as a consultant to AstraZeneca Pharmaceuticals LP and Eli Lilly & Co., and serves on the speakers’ bureau of AstraZeneca Pharmaceuticals LP, GlaxoSmithKline and Eli Lilly & Co.

J. Craig Nelson, MD – Presenter – serves as a consultant to Bristol-Myers Squibb, Corcept, Eli Lilly & Co., Merck and Co., Shire Pharmaceuticals and Sierra Neuropharmaceuticals.

Jerrold F. Rosenbaum, MD – Presenter – serves as a consultant to Auspex Pharmaceuticals, Neuronetics, Organon, Somaxon Pharmaceuticals and Supernius. He serves on the advisory board of Forest Pharmaceuticals, Eli Lilly & Co., Medavante, Novartis Pharmaceuticals Corp., Wyeth Pharmaceuticals, Neuronetics and Organon. Dr. Rosenbaum serves on the speakers’ bureau of Boehringer Ingelheim Italia, Reed Elsevier and Primedia Health Care. Dr. Rosenbaum has equity holdings in Compellis, Medavante and Somaxon Pharmaceuticals.

Norman Sussman, MD – Associate Dean for Postgraduate Programs and Planner – reports no relevant financial relationships.

The independent reviewer of this activity reports no relevant financial relationships.

ACKNOWLEDGEMENTS

This course is supported in part by
independent medical education grants from:

BRISTOL-MYERS SQUIBB CO. AND
OTSUKA AMERICA PHARMACEUTICALS, INC.

ELI LILLY & CO.

METHOD OF PARTICIPATION

In order to receive up to 3.75 CME Credits, you must view each of the presentations and complete the evaluation form. You will then be directed to your Letter of Credit.

COPYRIGHT STATEMENT

Unless otherwise noted, all documents accessed from this website are viewed as a precious resource of NYU and are Copyright NYU Post-Graduate Medical School, all rights reserved.